RT Journal Article
SR Electronic
T1 The NYCKidSeq project: study protocol for a randomized controlled trial incorporating genomics into the clinical care of diverse New York City children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.02.20186361
DO 10.1101/2020.09.02.20186361
A1 Odgis, Jacqueline A.
A1 Gallagher, Katie M.
A1 Suckiel, Sabrina A.
A1 Donohue, Katherine E.
A1 Ramos, Michelle A.
A1 Kelly, Nicole R.
A1 Bertier, Gabrielle
A1 Blackburn, Christina
A1 Brown, Kaitlyn
A1 Fielding, Lena
A1 Lopez, Jessenia
A1 Aguiniga, Karla Lopez
A1 Maria, Estefany
A1 Rodriguez, Jessica E.
A1 Sebastin, Monisha
A1 Teitelman, Nehama
A1 Watnick, Dana
A1 Yelton, Nicole M.
A1 Abhyankar, Avinash
A1 Abul-Husn, Noura S.
A1 Baum, Aaron
A1 Bauman, Laurie J.
A1 Beal, Jules C.
A1 Bloom, Toby
A1 Cunningham-Rundles, Charlotte
A1 Diaz, George A.
A1 Dolan, Siobhan
A1 Ferket, Bart S.
A1 Jobanputra, Vaidehi
A1 Kovatch, Patricia
A1 McDonald, Thomas V.
A1 McGoldrick, Patricia E.
A1 Rhodes, Rosamond
A1 Rinke, Michael L.
A1 Robinson, Mimsie
A1 Rubinstein, Arye
A1 Shulman, Lisa H.
A1 Stolte, Christian
A1 Wolf, Steven M.
A1 Yozawitz, Elissa
A1 Zinberg, Randi E.
A1 Greally, John M.
A1 Gelb, Bruce D.
A1 Horowitz, Carol R.
A1 Wasserstein, Melissa P.
A1 Kenny, Eimear E.
YR 2020
UL http://medrxiv.org/content/early/2020/09/03/2020.09.02.20186361.abstract
AB Background Increasingly, genomics is informing clinical practice, but challenges remain for medical professionals lacking genetics expertise, and in access to and clinical utility of genomic testing for minority and underrepresented populations. The latter is a particularly pernicious problem due to the historical lack of inclusion of racially and ethnically diverse populations in genomic research and genomic medicine. A further challenge is the rapidly changing landscape of genetic tests, and considerations of cost, interpretation and diagnostic yield for emerging modalities like whole genome sequencing.Methods The NYCKidSeq project is a randomized controlled trial recruiting 1,130 children and young adults predominantly from Harlem and the Bronx with suspected genetic disorders in three disease categories: neurologic, cardiovascular, and immunologic. Two clinical genetic tests will be performed for each participant, either proband, duo or trio whole-genome sequencing (depending on sample availability) and proband targeted gene panels. Clinical utility, cost and diagnostic yield of both testing modalities will be assessed. This study will evaluate the use of a novel, digital platform (GUÍA) to digitize the return of genomic results experience and improve participant understanding for English- and Spanish-speaking families. Surveys will collect data at three study visits; baseline (0 months), results disclosure visit (ROR1, +3 months), and follow up visit (ROR2, +9 months). Outcomes will assess parental understanding of and attitudes towards receiving genomic results for their child and behavioral, psychological and social impact of results. We will also conduct a pilot study to assess a digital tool called GenomeDiver designed to enhance communication between clinicians and genetic testing labs. We will evaluate GenomeDiver’s ability to increase the diagnostic yield compared to standard practices, to improve clinician’s ability to perform targeted reverse phenotyping, and to increase the efficiency of genetic testing lab personnel.Discussion The NYCKidSeq project will contribute to the innovations and best practices in communicating genomic test results to diverse populations. This work will inform strategies for implementing genomic medicine in health systems serving diverse populations using methods that are clinically useful, technologically savvy, culturally sensitive, and ethically sound.Competing Interest StatementEEK has received speaker honorariums from Regeneron and Illumina. NSAH was previously employed by Regeneron Pharmaceuticals and has received a speaker honorarium from Genentech. AB has received consulting fees from the American Board of Family Medicine outside the submitted work. JCB has received an honorarium from LivaNova. AR has received funding by TAKEDA for two clinical trials: HYQVIA in Pediatric CVID Patients (2018-2021) and SCIG Treatment for Chronic Inflammatory Demyelinating Polyneuropathy. RZ has received consulting fees from Sema4 outside the submitted work. All other authors declare they have no competing interest.Clinical TrialNCT03738098Funding StatementResearch reported in this publication was supported by the National Human Genome Research Institute and National Institute for Minority Heath and Health Disparities of the National Institutes of Health under Award Number 1U01HG0096108. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of Icahn School of Medicine at Mount Sinai and Albert Einstein College of Medicine approved this study protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data for this study will be shared in secure, access-restricted scientific research databases called The Database of Genes and Phenotypes (dbGAP) at the National Institutes of Health. Interpretations of clinical significance of variants from genetic testing will be submitted to the ClinVar database at the National Institutes of Health.List of abbreviationsTGPtargeted gene panelWGSwhole genome sequencingGUÍAGenomic Understanding, Information and Awareness applicationSOCstandard of careRORreturn of resultsMSIcahn School of Medicine at Mount SinaiEMAlbert Einstein College of Medicine/Montefiore Medical CenterNYGCNew York Genome Center